






















Is a cell block prepared from pleural fluid useful for the selection 
of medications in the treatment of recurrent breast cancer?
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Abstract
In the present study, we conducted immunostaining of a cell block preparation from pleural fluid in 
recurrent breast cancer and retrospectively examined its usefulness for the treatment of recurrence. The 
subject sample included six patients with recurrent breast cancer and pleural effusion. Cell blocks were 
prepared using pleural fluid collected by thoracocentesis and immunostained for ER, PgR, and HER2. On 
examining each respective clinical course, compared to the immunostaining findings of the primary lesion, 
the immunohistochemical findings had changed from those of the primary lesion in 4 out of 6 patients (66.7%). 
In three patients, it was thought that a change in treatment on the basis of immunohistological findings 
of the cell block might have affected the prognosis. We believe that immunohistostaining of cell blocks 
helps determine the heterogeneity of tumor cells. In selecting agents used in the treatment of recurrence, 
we believe it is important that after obtaining full informed consent from patients when they are in a 
good general condition and collecting pleural fluid and ascetic fluid for cell block immunohistostaining, the 
immunohistostaining results should reflect the decision to change the treatment policy.
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　 脳 転 移 を 合 併 し 全 脳 照 射 を 行 い ，
Trastuzumab+nab-paclitaxelで11か月の無増悪生
存期間（Progression Free Survuval: PFS）を得
たが再発４年後に死亡した。
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3図２　 免疫組織所見が原発巣と変化していた症例
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